Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
Open Access
- 1 September 2021
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 4 (9), e2126344
- https://doi.org/10.1001/jamanetworkopen.2021.26344
Abstract
COVID-19, which is due to infection with SARS-CoV-2, results in poor outcomes in patients with hematologic cancers (approximately 40% mortality rate).1,2 The efficacy of anti-SARS-CoV-2 mRNA vaccines has been successfully demonstrated in healthy populations3 and also has been reported in immunocompromised patients. Recently, we showed that a first injection of the BNT162b2 (Pfizer-BioNTech) vaccine induced an antibody response in 55% of 112 allogeneic hematopoietic stem cell transplant (HSCT) recipients.4 Here, we document the antibody response to a second dose of BNT162b2 vaccine in an extended cohort of 117 patients.This publication has 6 references indexed in Scilit:
- Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipientseJHaem, 2021
- Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant RecipientsJAMA, 2021
- Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumorsAnnals of Oncology, 2021
- Risk factors for a severe form of COVID‐19 after allogeneic haematopoietic stem cell transplantation: a Société Francophone de Greffe de Moelle et de Thérapie cellulaire (SFGM‐TC) multicentre cohort studyBritish Journal of Haematology, 2021
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine CandidatesThe New England Journal of Medicine, 2020
- Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry studyJournal of Hematology & Oncology, 2020